logo-cropped

Best Trade for Renewable Energy Group Is Short

Wednesday, 18 December 2013 09:45
NEW YORK (TheStreet) -- One consequence of the extended bull market is that many investors have been ignoring catalysts which clearly indicate that a stock is facing an impending nosedive. These investors suffer significant losses which are entirely avoidable. Gevo has already plunged by 40% in the past two weeks, while the two-day 20% drop in Plug Power may be just the beginning. For Renewable Energy Group, the expected drop could be far larger due…
Keep Fox News out of the classroom! Rupert Murdoch, Common Core and the dangerous rise of for-profit public education
Monday, 16 December 2013 07:45
How have the authors proposed we track the success of this reform? Testing, and lots of it. Along with the Common Core come two new major testing consortiums called SmarterBalanced and Partnership for Assessment of Readiness for College and Careers. Forget your No. 2 pencil; these aren’t the bubble tests you remember from school but adaptive computer testing that is required two to three times a year for every student in every grade. From the…
The Timeless Investment Every Serious Portfolio Should Have
Tuesday, 10 December 2013 15:04
Saddled with a pile of debt and a looming war with England, France was in desperate need of cash in 1803. So Napoleon took the same course of action that many publicly traded companies do today -- asset liquidation. The ensuing Louisiana Purchase was sealed for $15 million, or just 3 cents per acre. Thomas Jefferson's emissaries to France struck an incredible bargain. They acquired a territory that stretched from the Gulf Coast to Canada,…
Cancer Genetics, Inc. Will Showcase a Novel Diagnostic and Prognostic Test for Diffuse, Large B-Cell Lymphoma (DLBCL ...
Monday, 25 November 2013 08:15
RUTHERFORD, N.J., Nov. 25, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, is presenting data from its research collaboration with Memorial Sloan-Kettering Cancer Center ("MSKCC") at the American Society of Hematology ("ASH") 55th Annual Meeting and Exposition. CGI's poster presents data using the Company's proprietary microarray for mature B-cell neoplasms ("MatBA(R)"). The poster (#4259), entitled "Cross-Platform Assessment of Genomic Imbalance In Diffuse Large B-Cell Lymphoma…
Press Release
Tuesday, 12 November 2013 08:45
Senesco Technologies Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) announced today that it will make two presentations on its gene regulation technology (SNS01-T) for blood-borne cancer care at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition to be held from December 7-10th in New Orleans Louisiana. The abstracts are available on the ASH website at www.hematology.org. “We are pleased to be able to present a poster to provide an update on the current…
Senesco to Provide Update on Its Phase 1b/2a Trial Progress at 55th American Society of Hematology Annual Meeting
Tuesday, 12 November 2013 07:30
(function(){ var wrap = document.getElementById("yom-ad-LREC"); if (null == wrap) { wrap = document.getElementById("yom-ad-LREC-iframe") || {}; } var content = wrap.innerHTML || ""; if (content && content.substr(0, content.lastIndexOf(" BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Senesco Technologies, Inc. (“Senesco” or the “Company”) (SNTID) announced today that it will make two presentations on its gene regulation technology (SNS01-T) for blood-borne cancer care at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition to be held from December 7-10th in…
Geron Corporation Reports Third Quarter 2013 Financial Results
Sunday, 10 November 2013 08:15
Conference Call Scheduled for 4:30 p.m. EST Today, November 7th MENLO PARK, Calif., November 7, 2013 -- Geron Corporation (GERN) today reported financial results for the third quarter ended September 30, 2013. For the third quarter of 2013, the company reported a net loss of $8.3 million, or $0.06 per share, compared to $16.0 million, or $0.13 per share, for the comparable 2012 period. Net loss for the first nine months of 2013 was $29.1…
4 New Orleans Startups Compete For Cash
Friday, 08 November 2013 11:45
NEW ORLEANS (AP) -- Four New Orleans biotech startup companies will compete for an infusion of cash in front of a panel of industry experts and investors later this month. The New Orleans BioInnovation Center, a nonprofit technology business incubator, is holding the competition as part of a larger entrepreneur conference called Innovation Louisiana 2013 on Nov. 18-20. The Times-Picayune reports (http://bit.ly/1iRJLvE) that the competitors' have interests ranging from forensic DNA testing to treatment of…
Genmab to Present Product and Proprietary Technology data at American Society of Hematology Annual Meeting (ASH)
Thursday, 07 November 2013 08:46
Company AnnouncementSix Genmab abstracts accepted for presentation at ASHFirst preliminary data from Phase I/II daratumumab combination study in multiple myeloma Data from Phase III study of ofatumumab (COMPLEMENT 1) Copenhagen, Denmark; November 7, 2013 - Genmab A/S (GEN.CO) announced today that six Genmab abstracts which include data on daratumumab, ofatumumab and the novel HexaBody(tm) technology have been accepted for presentation at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition December 7-11 in…
MissionIR Releases Exclusive Audio Interview With CytRx Management
Thursday, 07 November 2013 07:45
ATLANTA, GA--(Marketwired - Nov 7, 2013) - MissionIR today announces the online availability of its interview with CytRx Corp. (NASDAQ: CYTR) President and Chief Executive Officer Steven Kriegsman, as well as the company's Vice President of Business Development and Investor Relations David Haen. The full audio interview is available at: http://cytr.missionir.com/interview.html. CytRx is a biopharmaceutical R&D company developing cancer drugs for several indications. The company's primary focus is on its proprietary delivery technology for potent…
Create your free online surveys with SurveyMonkey , the world's leading questionnaire tool.

La. US Senate Debate

Create your free online surveys with SurveyMonkey , the world's leading questionnaire tool.

latter-blum2

Share Bayoubuzz

Powered By JFBConnect